Bayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer’s Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will report...
Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further enhance speed of decision making. These changes reflect the...
Investigational results from FIND-CKD provide full efficacy and safety data and is the fifth consecutive Phase III clinical trial where KERENDIA met its primary endpoint—adding to a clinical trial program...
Presentations also include the INFINITY pooled analysis of KERENDIA ® (finerenone) across diabetic and non-diabetic chronic kidney disease.
Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA ® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD)...
Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA ® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant...
If approved for this investigational new use, KERENDIA ® (finerenone), a non-steroidal mineralocorticoid antagonist (MRA), would be the first MRA indicated for adults with type 1 diabetes...
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
3G Capital dumped Microsoft stock and piled into semiconductor names. Here's what the move says about AI investing right now, and whether MSFT remains a buy.
KEY FACTS: Regulatory submission is based on positive results from the Phase III OCEANIC-STROKE study OCEANIC-STROKE met the primary efficacy outcome...
Regulatory submission for first-line use of HYRNUO is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety in patients with advanced HER2 -mutated...